Bringhen, S
D'Agostino, M
De Paoli, L
Montefusco, V
Liberati, A M
Galieni, P
Grammatico, S
Muccio, V E
Esma, F
De Angelis, C
Musto, P
Ballanti, S
Offidani, M
Petrucci, M T
Gaidano, G
Corradini, P
Palumbo, A http://orcid.org/0000-0002-1763-6609
Sonneveld, P
Boccadoro, M
Article History
Received: 10 July 2017
Revised: 26 October 2017
Accepted: 31 October 2017
First Online: 16 November 2017
Competing interests
: SB has received honoraria from BMS, Celgene and Janssen-Cilag, and served on the advisory board for Amgen, Mundipharma and Karyopharm. LDP has received honoraria from Amgen, Celgene, Abbvie and Janssen. VM has received speaker’s bureau and advisory board for Amgen. PG has served on the advisory board for Takeda. MO has received honoraria from Celgene. MTP has received honoraraia from Celgene, Janssen-Cilag, BMS, Takeda and Amgen. GG has served on the advisory board for Amgen, Janssen, Gilead, Abbvie, Morphosys and Roche. AP is currently a Takeda employee. PS has received research support from Amgen, Celgene, Janssen and Karyopharm, and honoraria from Amgen, Celgene, Janssen, Karyopharm and BMS. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Abbivie and BMS, and research funding from Celgene, Janssen, Amgen, BMS, Mundipharma, Novartis and Sanofi.